TY - JOUR T1 - Beyond Deaths per Capita: Comparative CoViD-19 Mortality Indicators JF - medRxiv DO - 10.1101/2020.04.29.20085506 SP - 2020.04.29.20085506 AU - Patrick Heuveline AU - Michael Tzen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/13/2020.04.29.20085506.abstract N2 - Background Cumulative CoViD-19 deaths per capita is often used to compare the progression of the disease across populations. For more meaningful comparisons, this article discusses alternative measures based on well-established practices in demography.Methods Using extant estimates, we calculate a rate of CoViD-19 mortality to date for 263 countries, territories, provinces in China and US states. We indirectly age-and-sex standardize this rate using population age-and-sex distributions for 250 of them. Using extant projections, we calculate future unstandardized and standardized rates and the reduction in 2020 life expectancy at birth by sex for 103 countries and states.Results The highest rate to date is for New York, where it exceeded the 2017 Crude Death Rate between mid-March and mid-May. Relative to the US, standardization lowers European rates but increases rates in South America. Rates are projected to increase further and reductions in 2020 life expectancy at birth to amount to 1.1 to 1.2 years in Brazil, Chile and Peru. Larger reductions are projected for 6 US states, reaching 2.08 years for males in New York.Conclusions Lowering US life expectancy at birth to its lowest level since 2008, the projected.53-year reduction can be compared to the largest single-year decline the country experienced during the HIV epidemic, -.3 year, which also equaled the recent decline induced by opioid overdoses over several years. Uncertainty about CoViD-19 trajectories remains substantial, but these figures seem more likely to under-than to over-estimate the eventual mortality impact of CoViD-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Publicly available data onlyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available online and can be accessed directly or through a web scraping routine that we provide at https://github.com/statsccpr/ind-cov-mort https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 https://covid19.healthdata.org/ https://www.cdc.gov/nchs/nvss/vsrr/COVID19/index.htm ER -